CANNABIS CULTURE – Speakers from across North America connected at the first-ever Psychedelic Summit to provide education to the public on the new wave of modern consciousness-expanding medicine.
To begin the summit, which took place on February 25, 2021, Multidisciplinary Association of Psychedelic Studies (MAPS) Development Officer, Liana Gillooly, said her organization’s goal is to treat the root cause of trauma, which they believe is not being addressed by the pharmaceutical industry. “The vast majority of people who take psychedelics currently do so out of a clinical, therapeutic, or ceremonial environment.”
In a medical setting, MAPS has been focusing on MDMA-assisted therapy to combat PTSD, which affects over 350 million people globally. However, two-thirds of these people do not adequately respond to available treatments.
Suicide rates in the United States have increased 24% since the year 1999 and psychiatric drug spending has increased in that same time from $13 billion to over $50 billion. “It is clear the way the pharmaceutical industry understands and treats mental disorders